Open-label Study of TH-302 as Monotherapy and in Combination With Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma

Share this content:
Open-label Study of TH-302 as Monotherapy and in Combination With Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
 
Sponsors and Collaborators
Threshold Pharmaceuticals
 
Contact
Clarence Eng, MPH
650-474-8222
 
Investigator
Irene Ghobrial, MD
Massachusetts General Hospital
 
ClinicalTrials.gov Identifier
NCT01522872
 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs